Approval · Notice of Compliance 37015 · 2026
VARILRIX: Notice of Compliance 37015
Issued March 2, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37015
- Date
- March 2, 2026
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product Monograph update
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VARILRIX | Not yet assigned | — |
Medicinal ingredients
- VARICELLA-ZOSTER VIRUS VACCINE LIVE ATTENUATED (OKA-STRAIN) 1,995.2623 PFU per 0.5ML